About

About Aryastha Life Sciences Pvt Ltd Aryastha Life Sciences is a humanized, proprietary technology platform driven preclinical and translational Contract Research, Drug Discovery, Development, and Manufacturing Organization (CRDMO). Our capabilities span Discovery Chemistry, Discovery Biology, DMPK, In vivo Pharmacology, and Toxicology, seamlessly integrated with our proprietary platform Aryastha Biosolutions® and CDMO services. Our Aryastha Biosolutions® platform leverages humanized disease and toxicology models to deliver true end‑to‑end (E2E) solutions. It significantly de‑risks early-stage drug discovery and development attrition by enabling advanced screening and predictive insights across the entire drug discovery value chain. This platform integrates every vertical helping qualify late‑stage candidates with a higher level of confidence and substantially enhancing clinical success rates. Furthermore, our humanized models minimize animal usage by retaining the essential cellular and functional characteristics of human organs both healthy and diseased thus aligning with the FDA Modernization Act 3.0, which encourages alternatives to traditional animal testing. The platform’s precision in replicating human disease biology allows for highly predictive and reliable assessment of drug-like molecules well before entering clinical trials. These early predictive insights reduce development costs, shorten timelines, and accelerate time to market by significantly enhancing commercial value throughout the drug’s lifecycle.